IVAN ROSAS to Protein Kinase Inhibitors
This is a "connection" page, showing publications IVAN ROSAS has written about Protein Kinase Inhibitors.
Connection Strength
0.459
-
Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open Respir Res. 2025 Apr 10; 12(1).
Score: 0.176
-
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 12 15; 206(12):1463-1479.
Score: 0.150
-
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021 Mar 16; 22(1):84.
Score: 0.133